Kim EJ, Yoo C, Kang HJ, et al. - Given that there is no defined optimal systemic chemotherapy for combined hepatocellular‐cholangiocarcinoma (cHCC‐CCA) and changes have recently been made in the definition and classification of cHCC‐CCA in 5th edition of WHO classification, researchers here reviewed pathological findings with the new classification and evaluated the effectiveness of systemic chemotherapy in patients with unresectable/metastatic cHCC‐CCA. Assessing 254 patients with histologically confirmed cHCC‐CCA, they included 99 patients who received systemic chemotherapy for unresectable/metastatic disease. First‐line chemotherapies administered were sorafenib (n = 62) and cytotoxic chemotherapy (n = 37). Findings suggested no significant difference in the efficacy outcomes according to first‐line treatment between sorafenib and cytotoxic chemotherapy. Pathological findings were not identified as valuable for determining suitable therapeutic agents or assessing the prognosis.